Introduction {#H1-1-ZLD190062}
============

Hypertrophic cardiomyopathy (HCM) and valvular aortic stenosis can both present with left ventricular outflow obstruction and hypertrophy. In patients with aortic stenosis and coexisting HCM undergoing transcatheter aortic valve replacement (TAVR), this can pose a management dilemma, as one condition can modulate the effects of the other. Indeed, there has been anecdotal concern that treating the aortic valve prior to treating outflow tract obstruction may result in higher mortality due to exacerbation of subvalvular obstruction. There are limited data on optimal management or outcomes of coexisting HCM and aortic stenosis in patients who undergo TAVR. We conducted a retrospective cohort study using the National Inpatient Sample to identify the association of known HCM with outcomes following TAVR.

Methods {#H1-2-ZLD190062}
=======

We queried the 2012 to 2016 National Inpatient Sample to identify all patients (aged ≥18 years) who underwent TAVR and had coexisting HCM by using respective *International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM)* or *International Statistical Classification of Diseases, Tenth Revision, Clinical Modification Procedure Coding System (ICD-10-CM/PCS)* codes. Our primary outcome was in-hospital mortality. Categorical data were presented as counts and percentages, and continuous data as means with standard deviations or standard errors. Categorical variables were analyzed using Pearson χ^2^ tests, and continuous data were analyzed using *t* tests. We generated univariable and multivariable models to study the influence of HCM on outcomes, adjusting the model for relevant baseline characteristics. All analyses in our study were weighted using provided discharge weights to produce national estimates. Stata/IC software version 15.10 (StataCorp, LLC) was used for statistical analysis. Statistical significance was set at 2-tailed *P* \< .05. Given the deidentified nature of the National Inpatient Sample data, our study was exempt from approval from the institutional review boards of Mount Sinai St Luke's West and the Cleveland Clinic. This study was conducted as per the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

Results {#H1-3-ZLD190062}
=======

A total of 100 495 patients underwent TAVR during the study period. Of these, 230 patients (0.22%) had concomitant HCM. Compared with patients without HCM, those with HCM were more likely to be women (78.3% vs 46.7%; *P* \< .001) and obese (28.3% vs 15.4%; *P* = .02) but less likely to have prior coronary artery bypass grafting (0.7% vs 21.4%; *P* = .01). Baseline demographic characteristics are presented in [Table 1](#zld190062t1){ref-type="table"}.

###### Baseline Demographic Characteristics of Patients Undergoing Transcatheter Aortic Valve Replacement With and Without Concomitant HCM

  Characteristic                                                   No. (%)         *P* Value       
  ---------------------------------------------------------------- --------------- --------------- --------
  Women                                                            46 780 (46.7)   180 (78.3)      \<.001
  Age, mean (SD), y                                                80.72 (21.00)   80.99 (27.30)   .86
  Race                                                                                             
  White                                                            81 905 (87.2)   175 (83.3)      .01
  Black                                                            3935 (4.2)      20 (9.5)        
  Hispanic                                                         3850 (4.1)      5 (2.4)         
  Asian                                                            1125 (1.2)      0               
  Native American                                                  155 (0.2)       5 (2.4)         
  Other                                                            2940 (3.1)      5 (2.4)         
  Charlson Comorbidity Index score                                                                 
  0                                                                11 440 (11.4)   35 (15.2)       .04
  1                                                                16 195 (16.2)   70 (30.4)       
  2                                                                19 045 (19.0)   40 (17.4)       
  ≥3                                                               53 585 (53.4)   85 (37.0)       
  Mean annual income in patient zip code, percentile                                               
  0-25th                                                           21 090 (21.4)   45 (19.6)       .67
  26th-50th                                                        24 565 (24.9)   45 (19.6)       
  51st-75th                                                        25 855 (26.2)   55 (24.4)       
  76th-100th                                                       27 115 (27.5)   80 (35.6)       
  Insurance type                                                                                   
  Medicare                                                         90 475 (91.5)   205 (91.1)      .87
  Medicaid                                                         1095 (1.1)      5 (2.2)         
  Private                                                          6770 (6.9)      15 (6.5)        
  Uninsured                                                        540 (0.5)       0               
  Hospital characteristics                                                                         
  Region                                                                                           
  Northeast                                                        25 120 (25.1)   90 (39.1)       .10
  Midwest                                                          22 840 (22.8)   55 (23.9)       
  South                                                            33 590 (33.5)   50 (21.7)       
  West                                                             18 715 (18.7)   35 (15.2)       
  Bed size                                                                                         
  Small                                                            5165 (5.1)      15 (6.5)        .91
  Medium                                                           17 925 (17.9)   40 (17.4)       
  Large                                                            77 175 (77.0)   175 (76.1)      
  Urban hospital location                                          99 455 (99.2)   225 (97.8)      .29
  Teaching hospital                                                89 445 (89.2)   215 (93.5)      .34
  Patient comorbidities                                                                            
  Anemia (both deficiency and blood loss)                          3625 (3.6)      15 (6.5)        .29
  Prior stroke                                                     11 655 (11.6)   15 (6.5)        .27
  Prior myocardial infarction                                      13 215 (13.2)   15 (6.5)        .18
  Prior percutaneous coronary intervention                         12 985 (13.0)   35 (15.2)       .64
  Prior coronary artery bypass surgery                             21 465 (21.4)   15 (6.5)        .01
  Pulmonary hypertension                                           21 500 (21.4)   75 (32.6)       .08
  Coronary artery disease and coronary artery disease equivalent   62 005 (61.8)   115 (50.0)      .09
  Hypertension                                                     46 880 (46.8)   95 (41.3)       .45
  Obesity                                                          15 400 (15.4)   65 (28.3)       .02
  Dyslipidemia                                                     65 370 (65.2)   140 (60.9)      .53
  Peripheral vascular disease                                      18 190 (18.1)   30 (13.04)      .36
  Chronic lung disease                                             32 125 (32.0)   50 (21.7)       .12
  Congestive heart failure                                         64 370 (64.2)   135 (58.7)      .41
  Diabetes with and without complications                          36 005 (35.9)   60 (26.1)       .14
  Chronic kidney disease                                           36 090 (36.0)   75 (32.6)       .62

Abbreviation: HCM, hypertrophic cardiomyopathy.

Patients with HCM had greater incidence of in-hospital mortality (18.6% vs 2.91% for non-HCM; adjusted odds ratio \[aOR\], 7.33; 95% CI, 3.26-16.44; *P* \< .001), aortic dissection (2.33% vs 0.39%; aOR, 10.50; 95% CI, 2.53-43.53; *P* = .001), acute kidney injury (23.26% vs 12.24%; aOR, 2.62; 95% CI, 1.21-5.66; *P* = .01), and postoperative shock (16.28% vs 3.43%; aOR, 4.67; 95% CI, 1.97-11.05; *P* \< .001) ([Table 2](#zld190062t2){ref-type="table"}). There were no differences in terms of vasopressor use, pacemaker requirement, vascular injury, major bleeding requiring transfusion, and respiratory failure between the 2 groups.

###### Association of HCM With In-Hospital Outcomes

  Outcome                                Incidence, %   Unadjusted   Adjusted[^a^](#zld190062t2n1){ref-type="table-fn"}                                 
  -------------------------------------- -------------- ------------ ---------------------------------------------------- -------- -------------------- --------
  In-hospital mortality                  18.6           2.9          7.61 (3.52-16.44)                                    \<.001   7.33 (3.26-16.44)    \<.001
  Aortic dissection                      2.3            0.4          6.02 (0.82-43.71)                                    .07      10.50 (2.53-43.53)   .001
  Acute kidney injury                    23.3           12.2         2.17 (1.06-4.45)                                     .03      2.62 (1.21-5.66)     .01
  Postoperative shock                    16.3           3.4          5.48 (2.42-12.38)                                    \<.001   4.67 (1.97-11.05)    \<.001
  Vasopressor use                        4.7            1.9          2.46 (0.59-10.29)                                    .21      3.14 (0.97-10.19)    .06
  Pacemaker requirement                  2.3            7.0          0.31 (0.04-2.31)                                     .25      0.32 (0.004-2.36)    .26
  Complete heart block                   4.7            10.4         0.42 (0.10-1.75)                                     .23      0.60 (0.18-1.95)     .40
  Respiratory failure                    14.0           10.2         1.43 (0.60-3.39)                                     .41      1.8 (0.65-3.89)      .49
  Mechanical ventilation                 4.7            2.4          1.98 (0.47-8.26)                                     .34      1.45 (0.33-6.40)     .61
  Major bleeding requiring transfusion   18.6           18.1         1.03 (0.48-2.22)                                     .92      1.02 (0.49-2.12)     .94
  Vascular injury                        2.3            0.7          3.43 (0.47-25.10)                                    .22      4.17 (0.57-22.1)     .89

Abbreviations: HCM, hypertrophic cardiomyopathy; OR, odds ratio.

Variables adjusted were age, female sex, history of stroke, history of myocardial infarction, history of percutaneous coronary intervention, history of coronary artery bypass grafting, pulmonary hypertension, coronary artery disease, hypertension, obesity, dyslipidemia, peripheral vascular disease, chronic lung disease, diabetes, congestive heart failure, chronic kidney disease, anemia, Charlson Comorbidity Index category, elective procedure, insurance, teaching status of the hospital, and location of the hospital.

Discussion {#H1-4-ZLD190062}
==========

In this large, nationally representative study, we found that presence of HCM in patients undergoing TAVR was associated with markedly increased in-hospital mortality and complications. Current data on the association between HCM and postprocedural outcomes after TAVR are limited to small case reports and case series, which have described acute hemodynamic compromise after valve deployment.^[@zld190062r1],[@zld190062r2],[@zld190062r3]^ These cases highlight the difficulty in determining the contributions of each of the 2 obstructive lesions, and that provocable gradients might best be treated prior to TAVR to avoid the so-called suicide ventricle due to rapid removal of the afterload of aortic stenosis.^[@zld190062r1],[@zld190062r2],[@zld190062r3]^ The increased mortality observed in our study is likely attributable to unanticipated postprocedural hemodynamic compromise caused by unmasking of left ventricular outflow tract obstruction due to HCM, as previously reported.^[@zld190062r1],[@zld190062r3]^ The higher rates of acute kidney injury may be associated with postprocedural hemodynamic alterations and volume depletion due to the use of diuretics to optimize volume status prior to TAVR. The increased use of vasoactive medications in the HCM cohort in our study was also described by others^[@zld190062r2]^; these may be needed to maintain afterload to counter the left ventricular outflow tract obstruction caused by HCM, as well as to treat the development of cardiogenic shock. The main limitations of our study were retrospective observational study design, a smaller number of patients in the HCM group, possibility of coding errors, and lack of granular information on hemodynamic data. Nevertheless, our results highlight a need for further work to investigate the impact of HCM, if any, on long-term outcomes following TAVR.

In this study, concomitant HCM was associated with substantially worse in-hospital outcomes, including cardiogenic shock, renal failure, and death, in patients undergoing TAVR.
